PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2634.20%
Negative EBIT growth while TRVN is at 14.24%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-468.26%
Negative operating income growth while TRVN is at 14.24%. Joel Greenblatt would press for urgent turnaround measures.
-263.73%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-197.18%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-197.18%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
22.83%
Share count expansion well above TRVN's 0.01%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
22.83%
Diluted share count expanding well above TRVN's 0.01%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-36.01%
Negative OCF growth while TRVN is at 37.31%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-62.21%
Negative FCF growth while TRVN is at 37.31%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-319.11%
Negative 10Y OCF/share CAGR while TRVN stands at 49.15%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-319.11%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
52.30%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
-5305.80%
Negative 10Y net income/share CAGR while TRVN is at 60.68%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-5305.80%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-47.53%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-1146.88%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-1146.88%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
3.51%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Firm’s AR is declining while TRVN shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.29%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
10.32%
We have some new debt while TRVN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
402.37%
SG&A growth well above TRVN's 10.57%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.